BioCentury | Mar 19, 2007
Clinical News

Dextofisopam: Phase IIb start

...year, PARS will start a Phase IIb trial. PARS received dextofisopam through its acquisition of Vela Pharmaceuticals Inc....
BioCentury | Oct 30, 2006
Company News

Pharmos, Vela Pharmaceuticals deal

...million shares valued at $24.7 million (see BioCentury, Sept. 11). Pharmos Corp. (PARS), Iselin, N.J. Vela Pharmaceuticals Inc....
BioCentury | Sep 11, 2006
Company News

Pharmos, Vela Pharmaceuticals deal

...expected to close later this month or early next month. Pharmos Corp. (PARS), Iselin, N.J. Vela Pharmaceuticals Inc....
BioCentury | Mar 20, 2006
Company News

Pharmos, Vela deal

...Capital Markets advised PARS, and Cowen & Co. advised Vela. Pharmos Corp. (PARS), Iselin, N.J. Vela Pharmaceuticals Inc....
BioCentury | Apr 18, 2005
Strategy

Reprofiler report card

...development or, in some cases, medicinal chemistry. Jeff Calcagno, chief business officer and CFO at Vela Pharmaceuticals Inc....
...and hopes to partner one of its Phase III products this year. Vela: SWAT approach Vela Pharmaceuticals Inc....
BioCentury | Feb 14, 2005
Company News

Vela scientific advisory board update

Vela Pharmaceuticals Inc. , Ewing, N.J. Business: Neurology Appointed: Allen Mangel, VP and global head of medical services at Research Triangle Institute Health Solutions WIR Staff Neurology...
BioCentury | Jan 10, 2005
Clinical News

Dextofisopam: Phase II data

...endpoint. Dextofisopam patients reported relief for 57% of the time vs. 43% with placebo (p=0.033). Vela Pharmaceuticals Inc....
BioCentury | Sep 20, 2004
Company News

Vela scientific advisory board update

Vela Pharmaceuticals Inc. , Ewing, N.J. Business: Neurology Appointed: Praveen Tyle, SVP of R&D and CSO of Bausch & Lomb Inc. WIR Staff Neurology...
BioCentury | Jul 5, 2004
Clinical News

VPI-013: Phase II started

...in 250 patiens. The company in-licensed the compound from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan). Vela Pharmaceuticals Inc....
BioCentury | Jan 12, 2004
Company News

Vela scientific advisory board update

Vela Pharmaceuticals Inc. , Lawrenceville, N.J. Business: Neurology Appointed: George Clay, former COO of Kyowa Pharmaceuticals WIR Staff...
Items per page:
1 - 10 of 24
BioCentury | Mar 19, 2007
Clinical News

Dextofisopam: Phase IIb start

...year, PARS will start a Phase IIb trial. PARS received dextofisopam through its acquisition of Vela Pharmaceuticals Inc....
BioCentury | Oct 30, 2006
Company News

Pharmos, Vela Pharmaceuticals deal

...million shares valued at $24.7 million (see BioCentury, Sept. 11). Pharmos Corp. (PARS), Iselin, N.J. Vela Pharmaceuticals Inc....
BioCentury | Sep 11, 2006
Company News

Pharmos, Vela Pharmaceuticals deal

...expected to close later this month or early next month. Pharmos Corp. (PARS), Iselin, N.J. Vela Pharmaceuticals Inc....
BioCentury | Mar 20, 2006
Company News

Pharmos, Vela deal

...Capital Markets advised PARS, and Cowen & Co. advised Vela. Pharmos Corp. (PARS), Iselin, N.J. Vela Pharmaceuticals Inc....
BioCentury | Apr 18, 2005
Strategy

Reprofiler report card

...development or, in some cases, medicinal chemistry. Jeff Calcagno, chief business officer and CFO at Vela Pharmaceuticals Inc....
...and hopes to partner one of its Phase III products this year. Vela: SWAT approach Vela Pharmaceuticals Inc....
BioCentury | Feb 14, 2005
Company News

Vela scientific advisory board update

Vela Pharmaceuticals Inc. , Ewing, N.J. Business: Neurology Appointed: Allen Mangel, VP and global head of medical services at Research Triangle Institute Health Solutions WIR Staff Neurology...
BioCentury | Jan 10, 2005
Clinical News

Dextofisopam: Phase II data

...endpoint. Dextofisopam patients reported relief for 57% of the time vs. 43% with placebo (p=0.033). Vela Pharmaceuticals Inc....
BioCentury | Sep 20, 2004
Company News

Vela scientific advisory board update

Vela Pharmaceuticals Inc. , Ewing, N.J. Business: Neurology Appointed: Praveen Tyle, SVP of R&D and CSO of Bausch & Lomb Inc. WIR Staff Neurology...
BioCentury | Jul 5, 2004
Clinical News

VPI-013: Phase II started

...in 250 patiens. The company in-licensed the compound from Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan). Vela Pharmaceuticals Inc....
BioCentury | Jan 12, 2004
Company News

Vela scientific advisory board update

Vela Pharmaceuticals Inc. , Lawrenceville, N.J. Business: Neurology Appointed: George Clay, former COO of Kyowa Pharmaceuticals WIR Staff...
Items per page:
1 - 10 of 24